The increasing clinical use of positron-emitting radionuclides for tumour imaging has prompted researchers to develop newer GRPR antagonists labelled with 68Ga, 18F, or 64Cu [14], and it has been recently suggested that GRPR might complement prostate-specific membrane antigen (PSMA) for prostate cancer imaging [15]. Here, FOLH1 is linked to prostate carcinoma.